Can lowering inflammation protect your heart? new study explores link in arthritis patients

NCT ID NCT02714881

Completed Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how reducing inflammation might lower heart disease risk in people with rheumatoid arthritis. Researchers measured heart blood flow in 74 patients before and after treatment with certolizumab, a drug that fights inflammation. The goal was to see if better control of arthritis inflammation could improve heart health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Certolizumab
What this could lead to: If successful, this could show that controlling inflammation improves heart function in rheumatoid arthritis patients, pointing toward better cardiovascular risk management.
What could go wrong: This is a small, completed observational study with only 74 participants, so results may not apply to everyone. It does not test a new treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.